Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Table of Contents

January 2007; Volume 48,Issue 1 suppl

PET/CT in Cancer Patient Management - Johannes Czernin, Guest Editor

Cover image

Cover image expansion

ON THE COVER
At top is the PET-controlled therapy arm of a proposed design for randomized trials evaluating the impact of PET on disease management. Patients are randomized either to this arm or to standard therapy. At bottom are 18F-FDG PET/CT studies of a patient with soft-tissue sarcoma of the right thigh. The patient was treated with presurgical chemotherapy, and histopathologic analysis revealed 95% treatment-induced necrosis. This finding was reflected by a marked decrease in tumor 18F-FDG uptake. Quantitatively, tumor SUV decreased from 10.0 to 1.0. In contrast, there was no major change in tumor size on CT (arrows).
SEE PAGES 36S AND 36S

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 48 (1 suppl)
Journal of Nuclear Medicine
Vol. 48, Issue 1 suppl
January 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • PET/CT in Cancer Patient Management
  • Most Cited
  • Most Read
Loading
  • First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
  • Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View
  • Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
  • Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA
  • Fibroblast Activation Protein–Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire